p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
Year: 2019
Type: article
Abstract: anticancer activity of GSK343, thereby creating a vulnerability for treating HCC.
Source: PubMed
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2998620667